IGF-1 LR3 (Long R3) Dosage Chart
IGF-1 LR3 is a modified IGF-1 analog with an N-terminal extension and an Arg3 substitution that weaken IGF-binding-protein binding and extend circulation, studied for cell proliferation and muscle. Note two things up front: the 'Long' refers to the peptide extension, not the half-life, and the widely quoted 20-30 hour half-life is vendor lore rather than a clean human PK figure. Hypoglycemia is a real risk.
Half-life
Commonly cited ~20-30 hours (vendor figure, not a clean human PK value)
Format
Injectable
Purity
≥98%
Protocols
2 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Standard Research Convention
Dose
20-50mcg per day subcutaneous
Duration
4-week blocks, then off
The dose most research protocols circulate. Because IGF-1 LR3 is insulin-adjacent, blood glucose can drop; dosing with food is common. Human performance data does not exist, so this is convention, not evidence.
Protocol 2
Localized (site-injection) theory
Dose
20-50mcg into or near a trained muscle
Duration
Post-workout, as studied
The bodybuilding theory of injecting near a worked muscle for local effect. There is no human study showing injection-site-specific hypertrophy; treat it as an unproven hypothesis.
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
1mg vial
BAC water
2ml bacteriostatic water
Concentration
0.5mg/ml (500mcg/ml)
Dose / ml
50mcg = 0.1ml
Syringe units
10 IU per 50mcg on a U-100 syringe
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized: -20°C long-term, 2-8°C short-term. Reconstituted: refrigerate at 2-8°C and use within about 21-28 days. Some researchers reconstitute with a dilute acetic-acid solution; bacteriostatic water is the common choice. Do not freeze the reconstituted solution.
Research Considerations
Cautions
- HYPOGLYCEMIA: IGF-1 is an insulin cousin and can lower blood glucose sharply, even without insulin present. This is the primary acute risk; never dose fasted without understanding it.
- IGF-1R activation is a proliferative, anti-apoptotic signal, so elevated IGF-1 tone is a theoretical concern for cancer risk.
- Circulating half-life figures for IGF-1 LR3 are vendor claims, not established human pharmacokinetics.
- No human performance or hypertrophy trials exist. IGF-1 LR3 is a research compound not approved for human use; source only COA-verified material.
Ready to start your research
Get IGF-1 LR3 (Long R3) from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy IGF-1 LR3 (Long R3) nowResearch use only. Not medical advice. Browse all dosage charts